Clinical Trial Update: Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of ruxolitinib in relapsed or refractory T- or NK-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer Cell Lymphoma
• T-cell Lymphoma

Drugs mentioned

• Jakafi (ruxolitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma | Phase 2 | Status: RECRUITING